Page last updated: 2024-11-13

letter

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Letter: Work consisting of written or printed communication between individuals or between persons and representatives of corporate bodies. The correspondence may be personal or professional. In medical and other scientific publications the letter is usually from one or more authors to the editor of the journal or book publishing the item being commented upon or discussed. LETTER is often accompanied by COMMENT. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

levothyroxine sodium anhydrous : The sodium salt of L-thyroxine. It is used as replacement therapy in the treatment of hypothyroidism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23666112
CHEBI ID6446
SCHEMBL ID34102
MeSH IDM0025110

Synonyms (102)

Synonym
AC-919
sodium (2s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
CHEBI:6446 ,
levotiroxina de sodio
levothyroxinum natricum
levothyroxine sodique
levothyroxine sodium anhydrous
C08212
laevoxin
levoroxine
nsc-259940
euthyrox
sodium thyroxinate
dathroid
sodium thyroxin
sodium levothyroxine
thyroxine sodium
l-thyroxine sodium
l-thyroxine sodium salt
l-thyroxine monosodium salt
roxstan
ro-thyroxine
thyroxevan
sodium l-thyroxin
synthroid sodium
sodium thyroxine
letter
sodium l-thyroxine
25416-65-3
tyrosint
levotiroxina sodica [inn-spanish]
levothyroxinum natricum [inn-latin]
unithroid
levothyroxine sodique [inn-french]
3,3',5,5'-tetraiodo-l-thyronine, sodium salt
sodium-l-thyroxine
tiroidina
einecs 200-221-4
l-tyrosine, o-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt
thyradin
levothyroxin-natrium
thyroxinum natricum
thyradin s
thyroxin sodium
thyroxine sodique
tetroid
thyroxine, monosodium salt, l-
novothyrox
nsc 259940
thevier
berlthyrox
thyrax sodium
l-t4 sodium
(s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propionic acid sodium salt
sodium (s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propionate
T0245
tirosint
unii-054i36cpmn
thyroxinique
leventa
054i36cpmn ,
levothyroxine sodium [usan:inn]
l-tyrosine, o-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, sodium salt (1:1)
levotiroxina sodica
thyrosit
levolet
levothyroxine sodium tablets
AKOS015918420
levothyroxine sodium [who-dd]
levothyroxine sodium anhydrous [who-ip]
thyroxine sodium salt [mi]
levothyroxine sodium [inn]
levothyroxinum natricum anhydrous [who-ip latin]
EPITOPE ID:136776
levothyroxine sodium hydrate
sodium 4-o-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-l-tyrosine
l-thyroxine sodium xhydrate
SCHEMBL34102
AKOS024284731
AC-10210
sodium (s)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoate
J-524276
HY-18341B
CS-0031276
YDTFRJLNMPSCFM-YDALLXLXSA-M
l-thyroxinesodiumsalt,hydrate
Z1551967075
Q27107208
AMY14441
mfcd00002596
sodium;(2s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
CCG-270489
l-thyroxine (sodium)
D11113
levothyroxine sodium (inn)
DTXSID90883228
lt4 sodiuml-t4 sodium
lt4 sodium
levothyroxine for peak identification
AS-83570
levothyroxine sodium;t4 sodium
thyroxine soduim salt
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's2 (25.00)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 142.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index142.11 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index259.07 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (142.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies5 (62.50%)4.05%
Observational0 (0.00%)0.25%
Other2 (25.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]